Bertilimumab

Bertilimumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	CCL11 (eotaxin-1)
Clinical data
ATC code	none;
Identifiers
CAS Number	375348-49-5 ;
ChemSpider	none;
UNII	60879E4NED;
	(what is this?) (verify)

Bertilimumab is a human monoclonal antibody that binds to eotaxin-1, an important regulator of overall eosinophil function.

It was discovered by Cambridge Antibody Technology using their phage display technology.^[1] Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders.^[2]

In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc.^[3] iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications - a so-called 'search and development company'.^[4]

iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008 and, at that stage, planned to initiate a Phase II clinical trial in patients with vernal keratoconjunctivitis.^[5]

In March 2008, iCo announced iCo-008 had been in 126 patients in Phase I and II clinical trials. The drug substance had been manufactured by Lonza, in its cGMP facilities in Slough, UK. Subsequently, iCo moved the drug substance to a fill-finish site for the final stage of manufacturing. iCo reported that the iCo-008 drug product was within specifications and contained a high antibody yield.^[6]

References

^ Main S, Handy R, Wilton J, Smith S, Williams L, Fou LD, et al. (December 2006). "A potent human anti-eotaxin1 antibody, CAT-213: isolation by phage display and in vitro and in vivo efficacy". The Journal of Pharmacology and Experimental Therapeutics. 319 (3): 1395–404. doi:10.1124/jpet.106.110734. PMID 16973884. S2CID 20865759.
^ Ding C, Li J, Zhang X (November 2004). "Bertilimumab Cambridge Antibody Technology Group". Current Opinion in Investigational Drugs. 5 (11): 1213–8. PMID 15573873.
^ "Cambridge Antibody Tech. licenses monoclonal antibody for treatment of allergy disorders to iCo". iCo Therapeutics. Archived from the original on 2009-05-01. Retrieved 2009-08-01.
^ "iCo Therapeutics". iCo Therapeutics. Archived from the original on 2009-07-28. Retrieved 2009-08-01.
^ "iCo008". iCo Therapeutics. Archived from the original on 2009-07-28. Retrieved 2009-08-01.
^ "iCo Therapeutics Provides iCo-008 Phase II Clinical Update". iCo Therapeutics. Archived from the original on 2009-05-01. Retrieved 2009-08-01.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[pmid16973884-1] Main S, Handy R, Wilton J, Smith S, Williams L, Fou LD, et al. (December 2006). "A potent human anti-eotaxin1 antibody, CAT-213: isolation by phage display and in vitro and in vivo efficacy". The Journal of Pharmacology and Experimental Therapeutics. 319 (3): 1395–404. doi:10.1124/jpet.106.110734. PMID 16973884. S2CID 20865759.

[2] Ding C, Li J, Zhang X (November 2004). "Bertilimumab Cambridge Antibody Technology Group". Current Opinion in Investigational Drugs. 5 (11): 1213–8. PMID 15573873.

[3] "Cambridge Antibody Tech. licenses monoclonal antibody for treatment of allergy disorders to iCo". iCo Therapeutics. Archived from the original on 2009-05-01. Retrieved 2009-08-01.

[4] "iCo Therapeutics". iCo Therapeutics. Archived from the original on 2009-07-28. Retrieved 2009-08-01.

[5] "iCo008". iCo Therapeutics. Archived from the original on 2009-07-28. Retrieved 2009-08-01.

[6] "iCo Therapeutics Provides iCo-008 Phase II Clinical Update". iCo Therapeutics. Archived from the original on 2009-05-01. Retrieved 2009-08-01.

[1]